{
    "clinical_study": {
        "@rank": "85887", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver\n      tumor-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in\n      treating patients who have brain metastases."
        }, 
        "brief_title": "Monoclonal Antibody Therapy in Treating Patients With Brain Metastases", 
        "completion_date": {
            "#text": "May 2004", 
            "@type": "Actual"
        }, 
        "condition": "Metastatic Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the toxicity and maximum tolerated dose of 131-iodine-labeled\n      monoclonal antibody fragment Me1-14 F(ab')2 administered intrathecally in patients with\n      neoplasms metastatic to the leptomeninges. II. Identify objective therapeutic responses to\n      this treatment.\n\n      OUTLINE: Radioimmunotherapy. Iodine-131-Labeled Monoclonal Antibody Fragment Me1-14 F(ab')2,\n      131I-Me1-14 F(ab')2.\n\n      PROJECTED ACCRUAL: Three to 6 patients will be treated at each dose studied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed neoplasm that is recurrent in the\n        subarachnoid space Biopsy of recurrent lesion required if original diagnosis made more\n        than 2 years prior to entry and CSF cytology negative Radiographic evidence of measurable\n        lesion in the leptomeninges (by myelography, CT, or MRI) or cytologic evidence of\n        malignancy in the CSF Any type of neoplasm eligible provided tumor cells (tissue or CSF\n        preparation) bind significantly to intact monoclonal antibody Me1-14 IgG2a or to Me1-14\n        F(ab')2 Patency of subarachnoid pathways demonstrated by isotopic intraventricular flow\n\n        PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50-100%\n        Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at least\n        100,000/mm3 Hepatic: AST less than 1.5 times upper limit of normal (ULN) Alkaline\n        phosphatase less than 1.5 times ULN Renal: Creatinine less than 1.2 mg/dL Other: No\n        allergy to iodine Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks\n        since prior antineoplastic chemotherapy unless unequivocal evidence of tumor progression\n        No concurrent systemic chemotherapy Endocrine therapy: Corticosteroids allowed if at\n        lowest possible dose and stable for at least 10 days prior to entry Radiotherapy: At least\n        3 months since prior radiotherapy to site of measurable disease unless unequivocal\n        evidence of disease progression Surgery: Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002751", 
            "org_study_id": "1193", 
            "secondary_id": [
                "DUMC-1193-006R11", 
                "DUMC-1017-96-7R7", 
                "DUMC-1100-97-7R8", 
                "DUMC-1159-98-7R9", 
                "DUMC-1229-99-7R10", 
                "DUMC-657897", 
                "DUMC-997-95-7R6", 
                "NCI-V90-0052", 
                "NCI-H96-0010", 
                "CDR0000064687"
            ]
        }, 
        "intervention": {
            "intervention_name": "monoclonal antibody Me1-14 F(ab')2", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "keyword": "leptomeningeal metastases", 
        "lastchanged_date": "June 19, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DUMC-1193-006R11"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "PROTOCOL FOR A PHASE I STUDY OF INTRATHECAL MONOCLONAL ANTIBODY FRAGMENT 131I Me1-14 F(ab')2 IN PATIENTS WITH NEOPLASMS METASTATIC TO THE LEPTOMENINGES", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Darell D. Bigner, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002751"
        }, 
        "responsible_party": {
            "name_title": "Darell Bigner, MD", 
            "organization": "Duke UMC"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 1989", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2009"
    }, 
    "geocoordinates": {
        "Duke Comprehensive Cancer Center": "35.994 -78.899"
    }
}